Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases

被引：3
|
作者：
Hingorani, Mohan [1 ]
Dixit, Sanjay [1 ]
Pugazhenthi, Pattu [1 ]
Hawkyard, Simon [2 ]
Robertson, Andrew [2 ]
Khafagy, Richard [2 ]
机构：
[1] NHS Trust, Castle Hill Hosp, Dept Clin Oncol, Cottingham HU16 5JQ, East Riding Yor, England
[2] Scarborough Dist Gen Hosp, Dept Urol, Scarborough M1P 2V5, ON, Canada
来源：
CANCER BIOLOGY & MEDICINE | 2015年 / 12卷 / 01期
关键词：
Chemotherapy; Palliative; Prostate cancer; Radiotherapy;
D O I：
10.7497/j.issn.2095-3941.2014.0025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and abiraterone (n=1), who responded unusually after pRT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy. The possibility of pRT influencing metastatic disease in CRPC has not been previously reported, and raises the possibility of radiation-induced modulation of anti-tumor immune response mechanisms that may play a role in the restoration of response to systemic treatment.
引用
收藏
页码：60 / 63
页数：4
相关论文
共 50 条
  • [21] Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy
    Palma, David
    Tyldesley, Scott
    Pickles, Tom
    CANCER, 2008, 112 (09) : 1941 - 1948
  • [22] Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics
    Brady-Nicholls, Renee
    Zhang, Jingsong
    Zhang, Tian
    Wang, Andrew Z.
    Butler, Robert
    Gatenby, Robert A.
    Enderling, Heiko
    NEOPLASIA, 2021, 23 (09): : 851 - 858
  • [23] The Impact of Prostate-Specific Antigen and Gleason Scores on Cardiovascular Death in Prostate Cancer Patients after Radiotherapy or Chemotherapy: A Population-Based Study
    He, Huijuan
    Guo, Liyu
    Wang, Peipei
    Yang, Yuting
    Lu, Zhenxing
    Peng, Xiaoping
    Guan, Tianwang
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2025, 26 (02)
  • [24] Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy
    Lee, AK
    Levy, LB
    Cheung, R
    Kuban, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : 456 - 462
  • [25] Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer
    Nagata, Yujiro
    Matsukawa, Takuo
    Tomisaki, Ikko
    Fujimoto, Naohiro
    ANTICANCER RESEARCH, 2023, 43 (01) : 429 - 436
  • [26] Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer
    Miszczyk, Marcin
    Magrowski, Lukasz
    Masri, Oliwia
    Jablonska, Iwona
    Nowicka, Zuzanna
    Krzysztofiak, Tomasz
    Wojcieszek, Piotr
    Lipka-Rajwa, Aleksandra
    Ciepal, Jakub
    Depowska, Gabriela
    Chimiak, Krystyna
    Bylica, Gabriela
    Ploszka, Katarzyna
    Laszczych, Mateusz
    Majewski, Wojciech
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2022, 14 (01) : 15 - 22
  • [27] Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease
    Zhang, Qiang
    Helfand, Brian T.
    Carneiro, Benedito A.
    Qin, Weijun
    Yang, Ximing J.
    Lee, Chung
    Zhang, Weipeng
    Giles, Francis J.
    Cristofanilli, Massimo
    Kuzel, Timothy M.
    EUROPEAN UROLOGY, 2018, 73 (05) : 648 - 652
  • [28] PROSTATE-SPECIFIC ANTIGEN AFTER RADIOTHERAPY FOR PROSTATE-CANCER - A REEVALUATION OF LONG-TERM BIOCHEMICAL CONTROL AND THE KINETICS OF RECURRENCE IN PATIENTS TREATED AT STANFORD-UNIVERSITY
    HANCOCK, SL
    COX, RS
    BAGSHAW, MA
    JOURNAL OF UROLOGY, 1995, 154 (04) : 1412 - 1417
  • [29] Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients
    Ilknur Alsan Cetin
    Sıtkı Utku Akay
    Meric Sengoz
    BMC Urology, 22
  • [30] Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
    Hartrampf, Philipp E.
    Mihatsch, Patrick W.
    Seitz, Anna Katharina
    Solnes, Lilja B.
    Rowe, Steven P.
    Pomper, Martin G.
    Kuebler, Hubert
    Bley, Thorsten A.
    Buck, Andreas K.
    Werner, Rudolf A.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (08) : 1272 - 1278
12345